(Q41550265)

English

Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

pneumococcal vaccine

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Gregory A. Poland

4

object named as

Gregory A Poland

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

author name string

Kevin L Russell

1

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Carolyn I Baker

2

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Christian Hansen

3

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Margaret A K Ryan

5

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Mary M Merrill

6

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

language of work or name

0 references

publication date

8 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

1182-1187

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Protective Effects of the 23‐Valent Pneumococcal Polysaccharide Vaccine in the Elderly Population: The EVAN‐65 Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case–control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

An Epidemic of Pneumococcus Bronchopneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Respiratory diseases among U.S. military personnel: countering emerging threats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Pneumonia hospitalizations in the US Navy and Marine Corps: rates and risk factors for 6,522 admissions, 1981-1991.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Halting a pneumococcal pneumonia outbreak among United States Marine Corps trainees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Control of Streptococcus pneumoniae serotype 5 epidemic of severe pneumonia among young army recruits by mass antibiotic treatment and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

An outbreak of pneumonia associated with S. pneumoniae at a military training facility in Finland in 2006.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Cost effectiveness of vaccination against pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

A cost-benefit analysis of immunization for pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Economic evaluations of adult pneumococcal vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Detection of Mycoplasma pneumoniae and Mycoplasma genitalium in clinical samples by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

Detection of Chlamydia pneumoniae by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular approaches to diagnosis of pulmonary diseases due to Mycoplasma pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.12.058

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2014.12.058

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41550265&oldid=1924292641"